Smarter™ 7 × 19 CAR Construction Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

CAR engineered T cell therapy has developed rapidly in recent years. Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against solid tumors has lagged, potentially due to insufficient CAR-T cell expansion and persistence. To improve CAR-T cell efficacy, Creative Biolabs is proud to present a new generation CAR-T cells to express interleukin (IL)-7 and CCL19 (7 × 19 CAR-T cells), as these factors are essential for the maintenance of T-cell zones in lymphoid organs, with superior anti-tumor activity compared to conventional CAR-T cells.

Introduction of 7 × 19 CAR

Studies have shown that IL-7 and CCL19 are produced by T-region fibroblast reticulocytes, which are essential for the formation and maintenance of T-cell regions in lymphoid organs, in which T cells and DCs can be recruited from the periphery. Therefore, to improve CAR-T cell efficacy, we develop potent functional elements based on IL-7 and CCL19 signaling domains, which can mimic the function of T-zone reticular cells, and recruit T cells and DCs to tumor tissues to improve the therapeutic effect of CAR-T cells against solid tumors.

To obtain 7 × 19 CAR constructs, we generate a tandem construct encoding the CAR, IL-7, and CCL19 with two 2A peptide sequence between the genes. This novel, regulatable 7 × 19 system may promote the infiltration of dendritic cells (DC) and T cells into tumor tissues.

Schematic Schemas of conventional (Conv.) and 7×19 CAR (7×19) gene constructs.

Fig.1 Schematic Schemas of conventional (Conv.) and 7×19 CAR (7×19) gene constructs. (Adachi, 2018)

Features of our 7 × 19 CAR Service

Strong efficacy in both solid and liquid tumors with greater tumor penetration
Improved safety profile including moderate cytokine secretion and decreased off-tumor toxicity
Excellent expert team for offering real-time technical guidance
Advanced assay platforms to promote the data output
Timely data feedback to facilitate the process of your project

Creative Biolabs is a leading company which is dedicated to helping our worldwide customers shorten the discovery and development time in CAR-T cell therapy. We utilize unrivaled, proprietary drug design, study data, product candidate, advanced project life-cycle management, as well as real-time data to ensure the ideal outcomes. Through our full spectrum of early discovery, nonclinical and commercialization services, we are committed to developing the most promising CAR-T cell therapy product candidate for our clients.

For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

Adachi K, Kano Y, Nagai T, et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor[J]. Nature Biotechnology, 2018.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION